Call Options

7 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q1 2024

May 15, 2024

BUY
$25.89 - $29.73 $38.6 Million - $44.4 Million
1,492,100 Added 18.53%
9,545,700 $265 Million
Q4 2023

Feb 14, 2024

SELL
$26.13 - $33.94 $145 Million - $189 Million
-5,555,700 Reduced 40.82%
8,053,600 $232 Million
Q3 2023

Nov 14, 2023

BUY
$32.09 - $37.51 $206 Million - $241 Million
6,418,200 Added 89.25%
13,609,300 $451 Million
Q2 2023

Aug 14, 2023

BUY
$36.12 - $41.79 $68.9 Million - $79.7 Million
1,908,300 Added 36.12%
7,191,100 $264 Million
Q1 2023

May 15, 2023

SELL
$39.39 - $51.28 $135 Million - $176 Million
-3,422,900 Reduced 39.32%
5,282,800 $216 Million
Q4 2022

Feb 14, 2023

SELL
$41.75 - $54.5 $56.9 Million - $74.2 Million
-1,361,800 Reduced 13.53%
8,705,700 $446 Million
Q3 2022

Nov 14, 2022

SELL
$43.76 - $53.42 $7.11 Million - $8.68 Million
-162,500 Reduced 1.59%
10,067,500 $441 Million

Others Institutions Holding PFE

About PFIZER INC


  • Ticker PFE
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 5,612,349,952
  • Market Cap $157B
  • Description
  • Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under ...
More about PFE
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.